Navigating a product roadmap means making trade-offs on features and priorities. The real challenge comes when those decisions are less about what's next and more about placing calculated bets on what customers, technology, and the market will demand in the near future.
The day started like any other Tuesday for Ade, a founder building a data analytics tool for small clinics in Accra and Lagos. He walked into the weekly product meeting expecting to hash out the sprint priorities. On his way in, he scrolled past a news alert about a new open-source AI model achieving near-human accuracy on diagnostic tasks. He thought little of it, a fleeting thought in the usual Tuesday morning rush. He had a clear list of features: a new dashboard widget, improved CSV export, and a minor bug fix. These were solid, validated needs. His team, a compact group of two engineers and a product designer, had capacity for a tight two-week sprint. He believed they knew exactly what was next.
The Ground Shifts Beneath the Roadmap
The meeting began with his lead engineer, Emeka, opening with something unexpected. "I've been looking at the new 'MedScan' model that dropped yesterday," Emeka said, pulling up a GitHub page. "Its capabilities mean we could potentially automate initial data review, flagging anomalies before a human even touches the dataset. That's a huge value-add for our clinic customers who are swimming in patient data."
Ade felt a familiar tension. His roadmap was a carefully constructed bridge of validated needs. Emeka was proposing a detour into uncharted territory, a potentially groundbreaking feature based on a brand-new technology. This wasn't about optimizing existing features; it was about shifting the foundation. The question wasn't if they should build it, but when, and at what cost to the immediate, known problems they were solving. The clinics using their tool needed that reliable CSV export now, not a futuristic AI flagging system that might take months to integrate and stabilize. The problem was that Emeka was also right: that AI model could be a game-changer. The question then became, what was the real cost of not building it?
The Bet on Future Need
This wasn't a simple prioritization discussion. It was a forecast, a series of competing bets. The current roadmap was a bet on incremental improvement and known pain points. Emeka’s proposal was a bet on technological disruption and a future customer need that wasn't yet explicitly articulated. It was a bet on the velocity of AI adoption among small clinics, a demographic not always quick to embrace bleeding-edge tech. It forced Ade to consider a scenario where his competitors, or even new entrants, might leverage this kind of AI faster, making his current value proposition feel dated. This felt different from the time they had to pivot due to a funding delay. Then, the constraint was external and clear. Here, the constraint was a choice: known value versus potential future leverage.
Finding the Balance in Uncertainty
Ade pushed for a small, time-boxed exploration. "Emeka, can you and Sarah (the product designer) spend two days, just two days, on a quick proof-of-concept for MedScan? No integration, just mock-ups and a simple demonstration of what it could do for a single patient record." He stressed the constraints. "We'll run a quick survey with a few key clinics we have strong relationships with, show them the mock-up, and see their reaction. Is this a 'nice to have' or a 'must have' in six months?"
This approach turned the "roadmap meeting" into a strategic betting session. They weren't just prioritizing features. They were explicitly acknowledging the competing forces: immediate customer needs, emerging technological capabilities, and the market's unpredictable evolution. The two-day POC and customer survey was a way to gain information and reduce the risk of a larger, unvalidated bet. It meant delaying the CSV export by a few days, a calculated risk, but it also meant avoiding a six-week diversion into a feature no one might ultimately use. Or worse, missing the boat on something truly transformative.
The Roadmap Becomes a Living Forecast
By the end of the meeting, the roadmap was no longer a static list of tasks. It was a dynamic forecast, with branches representing validated paths and short, controlled experiments for potential future directions. The existing features still had their place, but a new, speculative branch had been added: "MedScan integration (Discovery Phase)." Ade knew that every feature decision carried an opportunity cost, but now he saw those costs as part of a larger, ongoing market dialogue. His job wasn't just to build what customers asked for, but to anticipate what they might not even know they needed yet. It was about Product Roadmaps: What Femi Learned From Unverified Features and the continuous calibration of bets.
Comments
No comments yet.